126 related articles for article (PubMed ID: 12031319)
1. Discovery of L-791,943: a potent, selective, non emetic and orally active phosphodiesterase-4 inhibitor.
Guay D; Hamel P; Blouin M; Brideau C; Chan CC; Chauret N; Ducharme Y; Huang Z; Girard M; Jones TR; Laliberté F; Masson P; McAuliffe M; Piechuta H; Silva J; Young RN; Girard Y
Bioorg Med Chem Lett; 2002 Jun; 12(11):1457-61. PubMed ID: 12031319
[TBL] [Abstract][Full Text] [Related]
2. CDP840. A prototype of a novel class of orally active anti-inflammatory phosphodiesterase 4 inhibitors.
Alexander RP; Warrellow GJ; Eaton MA; Boyd EC; Head JC; Porter JR; Brown JA; Reuberson JT; Hutchinson B; Turner P; Boyce B; Barnes D; Mason B; Cannell A; Taylor RJ; Zomaya A; Millican A; Leonard J; Morphy R; Wales M; Perry M; Allen RA; Gozzard N; Hughes B; Higgs G
Bioorg Med Chem Lett; 2002 Jun; 12(11):1451-6. PubMed ID: 12031318
[TBL] [Abstract][Full Text] [Related]
3. Substituted aminopyridines as potent and selective phosphodiesterase-4 inhibitors.
Côté B; Frenette R; Prescott S; Blouin M; Brideau C; Ducharme Y; Friesen RW; Laliberté F; Masson P; Styhler A; Girard Y
Bioorg Med Chem Lett; 2003 Feb; 13(4):741-4. PubMed ID: 12639571
[TBL] [Abstract][Full Text] [Related]
4. Comparison of inhibition of ovalbumin-induced bronchoconstriction in guinea pigs and in vitro inhibition of tumor necrosis factor-alpha formation with phosphodiesterase 4 (PDE4) selective inhibitors.
Muise ES; Chute IC; Claveau D; Masson P; Boulet L; Tkalec L; Pon DJ; Girard Y; Frenette R; Mancini JA
Biochem Pharmacol; 2002 Apr; 63(8):1527-35. PubMed ID: 11996895
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a substituted 8-arylquinoline series of PDE4 inhibitors: structure-activity relationship, optimization, and identification of a highly potent, well tolerated, PDE4 inhibitor.
Macdonald D; Mastracchio A; Perrier H; Dubé D; Gallant M; Lacombe P; Deschênes D; Roy B; Scheigetz J; Bateman K; Li C; Trimble LA; Day S; Chauret N; Nicoll-Griffith DA; Silva JM; Huang Z; Laliberté F; Liu S; Ethier D; Pon D; Muise E; Boulet L; Chan CC; Styhler A; Charleson S; Mancini J; Masson P; Claveau D; Nicholson D; Turner M; Young RN; Girard Y
Bioorg Med Chem Lett; 2005 Dec; 15(23):5241-6. PubMed ID: 16168647
[TBL] [Abstract][Full Text] [Related]
6. Discovery of new orally active phosphodiesterase (PDE4) inhibitors.
Ochiai H; Ishida A; Ohtani T; Kusumi K; Kishikawa K; Yamamoto S; Takeda H; Obata T; Nakai H; Toda M
Chem Pharm Bull (Tokyo); 2004 Sep; 52(9):1098-104. PubMed ID: 15340197
[TBL] [Abstract][Full Text] [Related]
7. Substituted 2-pyridinemethanol derivatives as potent and selective phosphodiesterase-4 inhibitors.
Ducharme Y; Friesen RW; Blouin M; Côté B; Dubé D; Ethier D; Frenette R; Laliberté F; Mancini JA; Masson P; Styhler A; Young RN; Girard Y
Bioorg Med Chem Lett; 2003 Jun; 13(11):1923-6. PubMed ID: 12749899
[TBL] [Abstract][Full Text] [Related]
8. Optimization of a tertiary alcohol series of phosphodiesterase-4 (PDE4) inhibitors: structure-activity relationship related to PDE4 inhibition and human ether-a-go-go related gene potassium channel binding affinity.
Friesen RW; Ducharme Y; Ball RG; Blouin M; Boulet L; Côté B; Frenette R; Girard M; Guay D; Huang Z; Jones TR; Laliberté F; Lynch JJ; Mancini J; Martins E; Masson P; Muise E; Pon DJ; Siegl PK; Styhler A; Tsou NN; Turner MJ; Young RN; Girard Y
J Med Chem; 2003 Jun; 46(12):2413-26. PubMed ID: 12773045
[TBL] [Abstract][Full Text] [Related]
9. Substituted 4-(2,2-diphenylethyl)pyridine-N-oxides as phosphodiesterase-4 inhibitors: SAR study directed toward the improvement of pharmacokinetic parameters.
Frenette R; Blouin M; Brideau C; Chauret N; Ducharme Y; Friesen RW; Hamel P; Jones TR; Laliberté F; Li C; Masson P; McAuliffe M; Girard Y
Bioorg Med Chem Lett; 2002 Oct; 12(20):3009-13. PubMed ID: 12270195
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, structure-activity relationships, and pharmacological profile of 9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro[1,4]diazepino[6, 7,1-hi]indoles: discovery of potent, selective phosphodiesterase type 4 inhibitors.
Burnouf C; Auclair E; Avenel N; Bertin B; Bigot C; Calvet A; Chan K; Durand C; Fasquelle V; Féru F; Gilbertsen R; Jacobelli H; Kebsi A; Lallier E; Maignel J; Martin B; Milano S; Ouagued M; Pascal Y; Pruniaux MP; Puaud J; Rocher MN; Terrasse C; Wrigglesworth R; Doherty AM
J Med Chem; 2000 Dec; 43(25):4850-67. PubMed ID: 11123995
[TBL] [Abstract][Full Text] [Related]
11. New orally active PDE4 inhibitors with therapeutic potential.
Ochiai H; Ishida A; Ohtani T; Kusumi K; Kishikawa K; Obata T; Nakai H; Toda M
Bioorg Med Chem Lett; 2004 Jan; 14(1):29-32. PubMed ID: 14684291
[TBL] [Abstract][Full Text] [Related]
12. Orally active PDE4 inhibitor with therapeutic potential.
Ochiai H; Ohtani T; Ishida A; Kishikawa K; Yamamoto S; Takeda H; Obata T; Nakai H; Toda M
Eur J Med Chem; 2004 Jul; 39(7):555-71. PubMed ID: 15236836
[TBL] [Abstract][Full Text] [Related]
13. 7-Methoxyfuro[2,3-c]pyridine-4-carboxamides as PDE4 inhibitors: a potential treatment for asthma.
Buckley GM; Cooper N; Davenport RJ; Dyke HJ; Galleway FP; Gowers L; Haughan AF; Kendall HJ; Lowe C; Montana JG; Oxford J; Peake JC; Picken CL; Richard MD; Sabin V; Sharpe A; Warneck JB
Bioorg Med Chem Lett; 2002 Feb; 12(3):509-12. PubMed ID: 11814830
[TBL] [Abstract][Full Text] [Related]
14. Pharmacology of N-(3,5-dichloro-1-oxido-4-pyridinyl)-8-methoxy-2-(trifluoromethyl)-5-quinoline carboxamide (SCH 351591), a novel, orally active phosphodiesterase 4 inhibitor.
Billah MM; Cooper N; Minnicozzi M; Warneck J; Wang P; Hey JA; Kreutner W; Rizzo CA; Smith SR; Young S; Chapman RW; Dyke H; Shih NY; Piwinski JJ; Cuss FM; Montana J; Ganguly AK; Egan RW
J Pharmacol Exp Ther; 2002 Jul; 302(1):127-37. PubMed ID: 12065709
[TBL] [Abstract][Full Text] [Related]
15. 7-Methoxybenzofuran-4-carboxamides as PDE 4 inhibitors: a potential treatment for asthma.
Buckley G; Cooper N; Dyke HJ; Galleway F; Gowers L; Gregory JC; Hannah DR; Haughan AF; Hellewell PG; Kendall HJ; Lowe C; Maxey R; Montana JG; Naylor R; Picken CL; Runcie KA; Sabin V; Tuladhar BR; Warneck JB
Bioorg Med Chem Lett; 2000 Sep; 10(18):2137-40. PubMed ID: 10999488
[TBL] [Abstract][Full Text] [Related]
16. The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4.
Hughes B; Howat D; Lisle H; Holbrook M; James T; Gozzard N; Blease K; Hughes P; Kingaby R; Warrellow G; Alexander R; Head J; Boyd E; Eaton M; Perry M; Wales M; Smith B; Owens R; Catterall C; Lumb S; Russell A; Allen R; Merriman M; Bloxham D; Higgs G
Br J Pharmacol; 1996 Jul; 118(5):1183-91. PubMed ID: 8818342
[TBL] [Abstract][Full Text] [Related]
17. Effects of a selective phosphodiesterase IV inhibitor (CDP-840) in a leukotriene-dependent non-human primate model of allergic asthma.
Jones TR; McAuliffe M; McFarlane CS; Piechuta H; Macdonald D; Rodger IW
Can J Physiol Pharmacol; 1998 Feb; 76(2):210-7. PubMed ID: 9635162
[TBL] [Abstract][Full Text] [Related]
18. In vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitor.
Bundschuh DS; Eltze M; Barsig J; Wollin L; Hatzelmann A; Beume R
J Pharmacol Exp Ther; 2001 Apr; 297(1):280-90. PubMed ID: 11259555
[TBL] [Abstract][Full Text] [Related]
19. Improvement of therapeutic index of phosphodiesterase type IV inhibitors as anti-Asthmatics.
Kim E; Chun HO; Jung SH; Kim JH; Lee JM; Suh BC; Xiang MX; Rhee CK
Bioorg Med Chem Lett; 2003 Jul; 13(14):2355-8. PubMed ID: 12824033
[TBL] [Abstract][Full Text] [Related]
20. Novel, potent, and selective phosphodiesterase-4 inhibitors as antiasthmatic agents: synthesis and biological activities of a series of 1-pyridylnaphthalene derivatives.
Ukita T; Sugahara M; Terakawa Y; Kuroda T; Wada K; Nakata A; Ohmachi Y; Kikkawa H; Ikezawa K; Naito K
J Med Chem; 1999 Mar; 42(6):1088-99. PubMed ID: 10090791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
